A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations

PTEN acts as a potent tumor suppressor within the PI3K/AKT/mTOR pathway. Germline mutations in the PTEN gene are a hallmark of PTEN hamartoma tumor syndrome, which includes Cowden syndrome, where they appear to elevate lifetime risk of cancer. Targeted AKT directed therapy has been proposed as an ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodón, Jordi, Funchain, Pauline, Laetsch, Theodore W, Arkenau, Hendrik-Tobias, Hervieu, Alice, Singer, Christian F, Murciano-Goroff, Yonina R, Chawla, Sant P, Anthony, Kristin, Yamamiya, Ikuo, Liu, Mei, Halim, Abdel-Baset, Benhadji, Karim A, Takahashi, Osamu, Delaloge, Suzette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2022
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334253/
https://www.ncbi.nlm.nih.gov/pubmed/36039910
http://dx.doi.org/10.2217/fon-2022-0305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334253/
https://www.ncbi.nlm.nih.gov/pubmed/36039910
http://dx.doi.org/10.2217/fon-2022-0305

Ejemplares similares